FDA Approves First Heart Valve Designed To Grow With Children

TL;DR

Prime Big Deal Days · Oct 6–7Offer from Amazon

Get self-care and calm essentials delivered free — and shop member deals

• Fast, free delivery on millions of items
• Access to Prime Big Deal Days deals on October 6–7
• Prime Video, Amazon Music and more included

Start your free Prime trial →Free trial for eligible customers · Cancel anytime

As an affiliate, we earn on qualifying purchases.Hide

The FDA approved the Autus Size-Adjustable Valve, a surgically implanted pulmonary valve for pediatric patients with congenital pulmonary valve disease. It can be expanded as a child grows, but the evidence submitted for approval includes a small study with six-month follow-up, and longer-term risks and benefits remain under study.

The U.S. Food and Drug Administration on October 1, 2026, approved the Autus Size-Adjustable Valve, a surgically implanted pulmonary heart valve for children with congenital pulmonary valve disease. Made by Edwards Lifesciences, the device can be widened after implantation as a child grows, a feature that may reduce the need for repeat open-heart surgery; the FDA says longer-term studies are still underway.

The valve can be implanted at about 13 millimeters in diameter, a size suitable for some toddlers and preschool-aged children, and later expanded with a balloon catheter to as much as 22 millimeters, comparable to an adult-sized pulmonary valve. The expansion is intended to let the implanted valve accommodate growth without replacing it through another open-heart operation. The FDA said two children whose valve performance began to decline as they outgrew the device had their valves expanded without invasive surgery. It cautioned that experience with this approach remains limited.

The Autus valve also uses polymeric material for its leaflets, the flaps that open and close to regulate blood flow. The FDA described it as the first U.S.-approved heart valve to use polymeric leaflets for any indication, rather than leaflets made from animal-derived tissue. The agency said one-year follow-up data suggest the synthetic leaflets hold up well over time. Traditional tissue valves can harden and break down faster in children, the FDA said, sometimes leading to earlier repeat surgery.

Approval relied on a clinical study that enrolled 62 pediatric patients at 12 U.S. sites. At six months, the first 60 patients had acceptable blood-flow performance and no more than mild leakage through the valve, according to the FDA. All patients in the study had a successful procedure. The agency reported no deaths, strokes, blood clots requiring additional treatment, or other clot-related complications during the reported period.

The study also recorded three valve-frame fractures and reduced movement in one leaflet in two patients. The FDA said none of those events caused symptoms. In two patients whose valve performance began to deteriorate as they outgrew the device, clinicians expanded the valves successfully. These findings are part of the safety picture, but the limited follow-up does not settle how the device performs over many years or across a larger group of children.

How Growth Adjustment Could Change Care

Children with congenital heart disease may need a pulmonary valve replacement because of leakage, or pulmonary regurgitation, that can develop after treatment for an abnormal valve. The FDA says significant leakage over time can weaken or enlarge the right ventricle, the chamber that pumps blood to the lungs. Doctors must weigh the risks of waiting against the possibility that a child who receives a replacement early will outgrow it and need another operation.

The adjustable design offers a potential way to address that dilemma: clinicians may be able to enlarge the implanted valve as a patient grows rather than replace it surgically. That could mean fewer operations for some children and less disruption for their families. But the FDA approval does not establish that every patient can avoid repeat surgery, or quantify how many operations the device may prevent. Longer-term evidence will be needed to show whether expansion reliably preserves valve function and improves outcomes.

The Need for Pediatric Valve Options

Congenital heart defects affect about one in every 100 births in the United States, according to the FDA. Pulmonary valve stenosis, in which the valve is narrowed, and pulmonary valve atresia, in which it does not form normally, can restrict blood flow from the heart to the lungs. The agency, citing the Centers for Disease Control and Prevention, says these two conditions together affect about 4,200 U.S. babies each year.

Some children treated for these defects later develop substantial pulmonary regurgitation and may need a replacement valve. The FDA said the Autus approval is the first pediatric approval to come through its Total Product Life Cycle Advisory Program, a voluntary program for medical-device developers. The agency had previously granted the device Breakthrough Device designation, which is intended to expedite development and review, but that designation is distinct from the approval now granted.

The FDA approved the valve through the premarket approval pathway, which it describes as its most stringent type of medical-device marketing application and uses for certain higher-risk devices. The agency says it reviewed scientific evidence, including clinical and nonclinical data, to assess whether there was reasonable assurance of safety and effectiveness for the intended use and whether benefits outweighed known risks.

“For far too long, children with congenital heart defects who need pulmonary valve replacement have had very limited surgical options, and those options have historically required multiple open-heart surgeries as children grow.”

— Kyle Diamantas, acting FDA commissioner

Long-Term Durability Still Under Study

The study results reported by the FDA cover six-month follow-up for the first 60 patients; the agency also cited one-year follow-up data suggesting the polymeric leaflets hold up well. Those periods do not establish how the valve or its frame will perform over the many years a child may need it. The three frame fractures and two cases of reduced leaflet movement were not symptomatic in the study, but their longer-term implications remain under investigation.

It is also not yet clear how often patients will need valve expansion, how long an expanded valve will remain functional, or how many repeat operations the device will ultimately prevent. The FDA said longer-term studies are being conducted to examine these risks and gather more evidence on whether expansion can maintain a functional valve. The approval announcement does not provide a complete account of eligibility criteria, expected follow-up schedules, or how outcomes may differ among patient groups.

Long-Term Studies Will Track Outcomes

Longer-term studies are expected to add evidence on valve durability, frame and leaflet performance, and whether balloon expansion can maintain adequate blood flow as children grow. The FDA said the studies are also intended to clarify whether expansion may lead to fewer surgical procedures. No further study milestones or completion dates were specified in the approval announcement.

For now, the approval makes the device available for its authorized pediatric use, while decisions about treatment remain a matter for patients’ care teams. Families and clinicians will need to weigh the potential to adjust the valve against the complications reported in the study and the limited duration of follow-up.

Key Questions

What did the FDA approve?

The FDA approved Edwards Lifesciences’ Autus Size-Adjustable Valve, a surgically implanted pulmonary heart valve for pediatric patients with congenital pulmonary valve disease.

How can the valve change size?

It can be implanted at about 13 millimeters and later widened with a balloon catheter to as much as 22 millimeters. The FDA says this may allow the valve to accommodate a child’s growth, but experience with expansion is limited.

What evidence supported approval?

The approval was based on a clinical study enrolling 62 pediatric patients at 12 U.S. sites. At six months, the first 60 patients had acceptable blood-flow performance and no more than mild valve leakage, according to the FDA.

Were complications reported?

Yes. The FDA reported three valve-frame fractures and reduced movement of one leaflet in two patients; none of those events caused symptoms. It reported no deaths, strokes, or blood clots requiring additional treatment during the study period described.

Does the approval mean children will not need another operation?

No. The valve may reduce the need for repeat open-heart surgery, but the FDA has not established how many operations it will prevent. Longer-term studies are underway to examine durability and whether expansion can maintain valve function.

Source: primary